24 Min Read
(Reuters) - For nearly two years, a killer stalked the patients of Providence Alaska Medical Centre.
It was a bacteria called Acinetobacter baumannii, a common cause of infections in hospitals. This one was different.
After a rash of mild cases in early 2011, doctors began seeing highly drug-resistant infections in patients, said Dr Megan Clancy, an infectious-disease specialist at the Anchorage, Alaska, hospital. And the bacteria was attacking more patients than just the severely ill ones who are the usual victims of drug-resistant “superbugs.”
Clancy took emergency measures. Infected patients were isolated. Staff and visitors had to adhere to strict hand-washing and other infection-control protocols. Furniture and equipment were scrubbed to remove a microbe that can stubbornly persist on all sorts of surfaces.
Clancy also contacted outside researchers for help. They found that a strain of the bacteria had acquired a rare combination of traits. Bacteria typically are either highly resistant to drugs or highly virulent. This strain was both.
Doctors quickly burnt through the antibiotics used as the second and third lines of defence against superbugs. This strain shook them off.
“When you start running out of medications, it gets pretty desperate,” Clancy said.
Eventually, they turned to colistin. This powerful antibiotic was largely abandoned in the 1960s for its toxic side effects. Out of necessity, it has become in recent years a weapon of last resort against the worsening superbug scourge.
But in some of the Alaska cases, even colistin didn’t work. For public health officials, that’s the nightmare scenario.
“It’s the worst of all possible worlds: You have a bacteria that is good at establishing infection, and it can’t be treated with antibiotics,” said Dr Robert Clifford, a microbiologist at the Walter Reed Army Institute of Research who studied the outbreak.
In early 2013, the infections stopped as mysteriously as they had begun. By then, the virulent strain had infected 19 patients and contributed to the deaths of five of them. A sixth died after contracting another highly resistant A. baumannii strain.
The Alaska outbreak, and others like it that make headlines with increasing frequency, illustrate a major weakness in the fight against superbugs: The arsenal of antibiotics is nearly empty. And significant financial and legal hurdles are getting in the way of the already challenging process of discovering effective new ones.
It’s been 30 years since the discovery of a new class of antibiotic that has hit the market. Each class is defined by its chemical structure, which determines how it kills bacteria. The longer an antibiotic is in use, the more time bacteria have to develop resistance to it. Penicillin and its ilk date back to World War Two, and resistance to this group is now widespread, as it is becoming for other extant classes.
Thirty-seven antibiotics are currently undergoing clinical trials, according to the Pew Charitable Trusts, which keeps track of the U.S. pipeline. Most, however, are based on existing drugs. While these derivatives are cheaper and easier to develop than new classes of drugs, bacteria have a head start in developing resistance to them.
Further, most drugs in the pipeline target so-called Gram-positive bacteria, a group that includes the well-known superbug methicillin-resistant Staphylococcus aureus (MRSA). But recently, the main emerging threats have come from the group known as Gram negatives, which are harder to treat because they are encased in tough membranes that repel many drugs. Among them: the lethal Acinetobacter that hit the Providence Alaska Medical Centre.
That’s why colistin has seen a resurgence in use. It is effective in particular against Gram-negative bacteria. Prescriptions of the drug dispensed by long-term care facilities and retail and online pharmacies increased 74 percent from 6,513 in 2005 to 11,322 in 2015, according to a Reuters analysis of data provided by QuintilesIMS, a healthcare research and services company in Durham, North Carolina. And those numbers don’t include prescriptions at regular acute-care hospitals.
Now, as happened in Alaska, doctors are encountering superbugs that are developing resistance to colistin, too.
“We are losing the standoff with pathogens,” said antibiotic researcher Kim Lewis, a Northeastern University biochemist. “Without antibiotics, essentially you do not have modern medicine.”
Previous stories in this series revealed how the lack of a coherent national surveillance system hinders the ability of federal and state public health officials to track what the U.S. government 15 years ago called a grave threat to public health.
Hundreds of thousands of antibiotic-resistant infections and tens of thousands of related deaths go uncounted each year. But even if they were closely tracked, the lack of new drugs to meet the rising tide of resistance means the toll will only mount.
To regain the advantage, medical science needs to overcome a daunting set of hurdles.
Bringing a new drug to market can cost upward of a billion dollars. The return on investment is much lower for antibiotics than it is for drugs that patients take for years to treat chronic conditions like high cholesterol or diabetes. Antibiotics are typically prescribed for short periods, usually seven to 14 days.
More recently, court rulings have made it difficult to patent the natural compounds from which most antibiotics are derived. And ironically, efforts to slow the development of resistance by curbing prescriptions have further damped the commercial allure of antibiotics.
Small wonder that Big Pharma has fled the business. In 1980, 36 large U.S. and European pharmaceutical companies were involved in research into new antibiotics. Today, there are four: Novartis AG, Merck & Co, GlaxoSmithKline Plc and Sanofi SA, said Karen Bush, a biochemistry professor at Indiana University Bloomington who studies the issue.
“It’s all about the bottom line,” Bush said.
To that end, Big Pharma tends to pump out new, more expensive versions of existing drugs. In a study published in May in the Annals of Internal Medicine, researchers found that almost no antibiotics approved by the Food and Drug Administration (FDA) since 2010 showed better results for patient survival or disability than older, cheaper ones.
For example, Merck’s Zerbaxa, a combination of drugs from two existing classes, cost more than $2,000 for a weeklong course to treat a urinary tract infection. That’s nearly 3,000 times the roughly 67-cent cost of seven days of a generic, levofloxacin, the study reported.
“As a group, these aren’t the antibiotics that health experts really need,” said Kevin Outterson, a Boston University law professor and co-author of the study. “None of them represent a novel class. None of them are really a breakthrough.”
In an emailed statement to Reuters, Merck said it spends significantly on research and development related to infectious diseases “to address unmet public health needs.” It cited a clinical trial showing that Zerbaxa was effective against urinary tract infections, including some that were resistant to levofloxacin.
Small biotechnology start-ups have filled the void left by Big Pharma. But these companies face the same hurdles. In addition, they lack the cash to shepherd promising discoveries through the multimillion-dollar process of clinical trials. The venture capitalists and other private investors they rely on expect returns in time frames shorter than scientific research allows.
“Forces well outside of science and medicine can come to bear and have disastrous consequences” on drug development, said biochemist William DeGrado, a professor of pharmaceutical chemistry at the University of California, San Francisco.
The company that he and a team at the University of Pennsylvania founded 14 years ago to develop what would be the first drug in a new class of antibiotic went bankrupt after investor support withered. Under new owners, the drug is still awaiting funding for clinical trials.
Government has attempted to prime the process. Under its 2014 national action plan to combat the superbug crisis, President Barack Obama’s administration got Congress to approve increased funding for public health agencies.
The National Institutes of Health received a $100 million increase, to about $413 million, in part for grants to fund work on new antibiotics. And the Biomedical Advanced Research and Development Authority (Barda), an office in the Department of Health and Human Services that develops medical products for emergencies, funds some trials and research. Barda also is underwriting a programme to support pre-trial work on promising compounds.
In 2012, a new law empowered the FDA to designate certain drugs “qualified infectious disease products.” The drugs can get priority review for approval, and if approved, may be eligible for an additional five years of market exclusivity. Most of the 37 drugs now in the pipeline have received the designation.
In the four years since the law took effect, there has been a “mild uptick in antibacterial drug development,” the FDA said. However, it added, “the pipeline remains very fragile.”
On a bright summer day in June 2000, William DeGrado sketched a ribbon-like molecule on a piece of scrap paper.
It may not have looked like much, but it so excited the biochemist and his team of fellow researchers at the University of Pennsylvania in Philadelphia that they all signed the sketch and set to work building the molecule in a laboratory.
The source of their excitement was the molecule’s resemblance to antimicrobial peptides, or AMPs. These tiny proteins are produced by the body’s own tissues as a first line of defence against all sorts of infections. AMPs don’t have to enter a pathogen to kill it — they literally punch holes through bacteria cell walls. That means they can kill both Gram-positive and thick-skinned Gram-negative bugs.
Scientists have long recognised the potential of AMPs. But previous efforts to turn the proteins into effective drugs failed: The products were too costly, too toxic or too chemically unstable. DeGrado’s sketch suggested it was possible to create a synthetic version of an AMP without those drawbacks.
“I thought, if it works, we’ve got a simple drug that would be cheap to make that could go to the developing world and cure all sorts of things,” said Michael Klein, a computational chemist who was tasked with creating computer models of the molecule.
Within two years, they had formed a company, called PolyMedix, and raised a few million dollars in funding from NIH grants and private investors. Soon after, they obtained patents and published their first scientific paper on the potential of their new drug, eventually called brilacidin.
In early lab tests, the molecule showed potency against bacteria known for resistance to powerful drugs, including Gram positives and well-known Gram-negative killers Klebsiella pneumoniae and Escherichia coli. Even more encouraging, testing showed bacteria had little propensity to acquire resistance to the drug.
As they barreled toward clinical trials to test the safety and efficacy of the drug, they raised more money by getting PolyMedix listed on the over-the-counter market. “We believe it is less likely that resistance will develop against our product candidates compared with conventional antibiotic drugs,” the company told investors in 2006.
But the company was burning through cash. By 2012, after the first phase II trials of brilacidin, PolyMedix had accumulated a $96 million deficit, according to regulatory filings.
Investors grew impatient with the slow pace of the trials and the fact that the drug proved more effective against Gram-positive infections than harder-to-kill Gram negatives, said Richard Scott, a PolyMedix founder.
On April 1, 2013, after defaulting on a loan, PolyMedix declared bankruptcy. “It just didn’t work, given the reality of having to make progress in very short time periods (to offer) a return on investment,” Scott said.
Another small biotechnology company, Cellceutix Corp, paid $5 million in cash and stock for PolyMedix’s assets.
Cellceutix is housed in the first floor of a nondescript grey building in the back of an office park in Beverly, Massachusetts, near Boston — a far cry from the sprawling research centres Big Pharma operates. On a recent November day, just eight people were at work, out of total staff of 18.
In 2014, Cellceutix completed a second phase II trial of brilacidin. It found that a single dose of the drug was as effective against MRSA as a weeklong course of daptomycin, a popular antibiotic widely used in hospitals against the superbug.
A phase III trial - typically larger and more expensive than earlier trials - has been planned for more than a year now. But the company needs $30 million to move forward, chief scientist Krishna Menon said. It’s also seeking a special assessment from the FDA to speed up the trial and approval process.
”We have the contractors, the medicine, the vials all ready!” Menon said. “Everything is set.”
Investors, however, haven’t shown much interest in advancing the process. Some sued the company last year, alleging that Cellceutix misled them about the potency of brilacidin against Gram-negative bugs. A judge in federal court in Manhattan threw out the case last June, but the damage was done. Shares of Cellceutix have dropped to around $1.15 from more than $4.50 after the successful phase II trial.
Meanwhile, scientific interest in the potential of AMPs has only grown. A Ph.D student in Australia made international headlines in September after she created an AMP-based molecule that has the potential to kill Gram-negative pathogens, including those resistant to colistin. But the research is still in its earliest stages and far from clinical trials.
Resistance can develop fast, and is made worse through over-prescribing and misuse of drugs. To preserve existing antibiotics, public health officials have urged hospitals and doctors to implement “stewardship” programs to reduce unnecessary prescriptions and hold critical drugs in reserve for when others fail.
Beginning Jan. 1, 2017, the Joint Commission, the nonprofit group that accredits U.S. healthcare facilities, will require hospitals and nursing care centres to implement stewardship programs. And the Centers for Medicare & Medicaid Services proposed a rule in June that would require hospitals to have stewardship programs to participate in the two huge government insurance programs it administers. In 2014, California became the first state to enact a law that mandates stewardship programs.
Suburban Hospital, in Bethesda, Maryland, adopted a stewardship programme in July 2015 to comply with new Joint Commission standards. In the first year, the hospital’s antibiotic use fell about 7 percent, said Julie Trivedi, hospital epidemiologist and director of antimicrobial stewardship. That saved the hospital nearly $200,000 on antimicrobial drugs.
“Infectious disease is not like cardiology, where the latest drug on the market is the one you want to use,” Trivedi said. “Infectious disease physicians drive that beat-up Beetle until the car falls apart … It’s about utilizing the available drugs before moving on to new drugs.”
GlaxoSmithKline’s most promising experimental antibiotic, gepotidacin, is now in phase II clinical trials. If approved, it will be used as a last resort against superbugs. The company has been able to shepherd the drug through expensive research and clinical trials with support from the federal Barda programme, said David Payne, head of GlaxoSmithKline’s Antibacterial Discovery Performance Unit.
But, he said, since the drug should be used only when it’s “desperately needed ... that creates a huge challenge in creating a viable return on investment.” He said the company has invested roughly $1 billion in antibiotic research over the past decade.
In early 2015, researchers Kim Lewis and Slava Epstein at Northeastern University in Boston published an article in the journal Nature announcing the discovery of teixobactin, a compound that appeared to kill Gram-positive bacteria without any indications of resistance.
Major media carried the news. The New York Times wrote that teixobactin could “help solve an urgent global problem” by ushering in a new class of antibiotic for the first time in decades.
Since then, NovoBiotic Pharmaceuticals LLC, the Cambridge, Massachusetts, company the researchers founded to commercialise their products, has been receiving letters and emails from people around the world.
“I have chronic urinary tract infection, and would like to know when will be available teixobactin for sale?” wrote a patient from Brazil. Another, from Romania, wrote: “I have some big problems in my life because of staphylococcus aureus ... I would like to participate in a programme for testing.”
“It’s really sad,” said NovoBiotic President Dallas Hughes, “because I have to tell them we are two years away from clinical trials.” The company’s researchers are still tinkering with how the drug dissolves in blood, to make it suitable for use in humans.
The excitement surrounding teixobactin isn’t just about its potential to kill bacteria. It’s also about how the compound was isolated – from a soil microbe that could not previously be studied because it could not be grown in a lab.
Lewis and Epstein invented a way to cultivate it and other previously out-of-reach soil and marine bacteria. Developed in Epstein’s lab, the isolation chip, or “iChip,” holds out the promise of unearthing all sorts of natural compounds that could be turned into life-saving drugs.
That innovation, which is patented, addresses a fundamental issue that for decades has hindered development of new classes of antibiotics.
Bacteria started showing resistance to penicillin as early as 1940 – just 12 years after the drug’s discovery, and even before it was mass-produced to treat British and U.S. troops during World War Two. That didn’t cause much concern. New classes of antibiotics were regularly coming to market, derived mostly from compounds produced by bacteria.
But by the 1980s, scientists had pretty much exhausted the supply of available compounds. Untold multitudes of potentially beneficial compounds were locked away in bacteria that couldn’t be grown in a lab. That’s a major reason why Big Pharma started exiting antibiotic research in the 1980s, and why most investment today goes toward developing drugs that are analogs of old ones.
The iChip gets around the problem. Volunteers from across the United States send soil to NovoBiotic to help its scientists find new medicines. On a shelf in a back room of the company’s single-floor premises sit dozens of clear plastic bags of soil, each labelled by location: “Jackson Falls, woods edge, New Hampshire,” “Warwick, RI, woods.”
So far, NovoBiotic has isolated more than two dozen compounds using iChip technology, though only teixobactin and one other are being developed as possible drug candidates.
With teixobactin and the iChip, NovoBiotic has also attracted $35 million from angel investors and through grants from the Bill and Melinda Gates Foundation and the NIH.
But while NovoBiotic is benefiting from the federal government’s efforts to promote drug development, it and other biotech companies are also confronting a new legal impediment.
Two U.S. Supreme Court rulings, in 2012 and 2013, have made it harder to patent products derived from nature. The cases dealt with patent protection for human genes and blood products. But the court’s decisions have been interpreted more broadly to limit intellectual property rights on all sorts of natural phenomena, including chemicals with antibiotic properties.
About 70 percent of the bacteria-fighting drugs approved worldwide since 1981 are natural products or derived from them, according to David Newman, former chief of the natural products branch at the National Cancer Institute, who continues to publish studies on the topic.
But since 2014, the U.S. Patent and Trademark Office has been rejecting applications for patents on natural products.
A patent allows for a limited time period of exclusive sales during which investors and companies can recoup their development costs. Without a patent, “anyone and your uncle can make the drug and sell it for less, so why take it to market?” said Ronald Evens, a researcher at the Tufts Center for the Study of Drug Development.
In NovoBiotic’s first attempt to patent teixobactin, in 2014, the patent office said it was “an isolated compound from nature” and not eligible for protection. The agency allowed NovoBiotic to patent only the method of treating patients, according to documents reviewed by Reuters.
That means the company holds a patent on specific uses, like administering the drug at a certain dosage, intravenously, for MRSA.
The company in August obtained a second teixobactin-related patent, this time as a “pharmaceutical composition,” incorporating other ingredients mixed with the drug itself.
Such patents offer less protection from rivals that design a drug based on the same natural compound but using different mixtures and treatment methods. “Under these circumstances, if someone were to make just the compound, they would not infringe” on the patent, said biotechnology patent lawyer Kevin Noonan, a partner at Chicago-based firm McDonnell Boehnen Hulbert & Berghoff.
Some lawyers and doctors argue that fewer protections could promote scientific research by eliminating the monopolies patents create. But for biotech companies like NovoBiotic, the difficulty of obtaining patents on natural compounds could be problematic for drug development.
Brilacidin, the drug that Cellceutix is working on, is safe. It was patented before the rulings, and besides, it isn’t a natural compound but merely mimics one. But rejections are hitting others seeking to patent AMPs or close copies of them.
In August, the U.S. Patent and Trademark Office rejected an application by a medical research arm of a foundation associated with German auto supplier Robert Bosch Gmbh to patent a fragment of a human AMP called defensin. In its application, the foundation cited its own research showing that the molecule was effective against Gram-negative and Gram-positive bacteria, non-toxic and easy to manufacture.
The patent officer examining the case said it was not “markedly different from what exists in nature.”
Federal courts are in accord with the patent office. In six of seven cases in which natural products or diagnostic tests were at issue since 2012, courts have either cancelled or rejected the patents. The Supreme Court has signalled its agreement with the trend so far, declining to review one case that had been appealed to the high court earlier this year.
“Research and development is complex, risky and expensive,” said Corey Salsberg, head of intellectual property policy at Novartis, who wrote a brief for the Supreme Court on the topic. By restricting what drugs can be patented, he says, “you’re telling companies … ‘Don’t bother putting your resources here.’”
Reporting by Andrew Chung in Boston, Yasmeen Abutaleb in San Francisco and Deborah J. Nelson in Washington. Additional reporting by Ryan McNeill in New York. Edited by John Blanton